Payload Information
General Information of This Payload
| Payload ID | PAY0TRFQG |
|||||
|---|---|---|---|---|---|---|
| Name | CPTS-1 |
|||||
| Synonyms |
CPTS-1
Click to Show/Hide
|
|||||
| Target | DNA topoisomerase I (TOP1) | |||||
| Formula | C26H19N3O6 |
|||||
| Isosmiles | O=C1OCC(C2=O)=C([C@@](CC)1O)C=C3C4=NC5=CC6=C(C=C5C(C7=CC=NC=C7)=C4CN23)OCO6 |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C26H19N3O6/c1-2-26(32)17-8-19-23-15(10-29(19)24(30)16(17)11-33-25(26)31)22(13-3-5-27-6-4-13)14-7-20-21(35-12-34-20)9-18(14)28-23/h3-9,32H,2,10-12H2,1H3/t26-/m0/s1
|
|||||
| InChIKey |
RJVKZAFIZSNBNF-SANMLTNESA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
469.453 |
Polar area |
112.77 |
||
Complexity |
1608.41049 |
xlogp Value |
2.8703 |
|||
Heavy Count |
35 |
Rot Bonds |
2 |
|||
Hbond acc |
9 |
Hbond Donor |
1 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Cellular activity | 10 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 27 | % |
4T1 cells
|
Malignant neoplasms of the mouse mammary gland
|
||
| Half Maximal Inhibitory Concentration (IC50) | <0.013 | nM |
SK-BR-3 cells
|
Breast adenocarcinoma
|
[1] | |
| Half Maximal Inhibitory Concentration (IC50) | <0.013 | nM |
SK-BR-3 cells
|
Breast adenocarcinoma
|
[1] | |
| Half Maximal Inhibitory Concentration (IC50) | <0.05 | nM |
MDA-MB-468 cells
|
Breast adenocarcinoma
|
[1] | |
| Half Maximal Inhibitory Concentration (IC50) | <0.05 | nM |
MDA-MB-468 cells
|
Breast adenocarcinoma
|
[1] | |
| Half Maximal Inhibitory Concentration (IC50) | <0.05 | nM |
NCI-N87 cells
|
Gastric tubular adenocarcinoma
|
[1] | |
| Half Maximal Inhibitory Concentration (IC50) | <0.05 | nM |
NCI-N87 cells
|
Gastric tubular adenocarcinoma
|
[1] | |
| Half Maximal Inhibitory Concentration (IC50) | 2.67 | nM |
SW620 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 93.47 | nM |
2008 cells
|
Ovarian carcinoma
|
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
HER2-14 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
145.43䔿.69 ng/mL
|
High HER2 expression (HER2+++; >300,000 HER2 molecules/cell) | ||
| Method Description |
Cells were distributed into 96-well white round-bottom plates, with each well receiving 1000 cells in RPMI-1640 medium supplemented with 10% FBS. Following a 24-hour incubation period, diluted compounds were introduced to the wells. After 144 hours, a CellTiter-Glo luminescent cell viability assay (Promega, Madison, WI, USA) was performed to assess cell viability. The luminescent readings were normalized as percentages relative to untreated cells, and the IC50 values for each compound were determined.
Click to Show/Hide
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
HER2-16 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
166.41䕋.34 ng/mL
|
High HER2 expression (HER2+++; >300,000 HER2 molecules/cell) | ||
| Method Description |
Cells were distributed into 96-well white round-bottom plates, with each well receiving 1000 cells in RPMI-1640 medium supplemented with 10% FBS. Following a 24-hour incubation period, diluted compounds were introduced to the wells. After 144 hours, a CellTiter-Glo luminescent cell viability assay (Promega, Madison, WI, USA) was performed to assess cell viability. The luminescent readings were normalized as percentages relative to untreated cells, and the IC50 values for each compound were determined.
Click to Show/Hide
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
References